2. Signaling Pathways
  3. Protein Tyrosine Kinase/RTK
  4. FGFR
  5. FGFR4 Isoform
  6. FGFR4 Inhibitor

FGFR4 Inhibitor

FGFR4 Inhibitors (49):

Cat. No. Product Name Effect Purity
  • HY-163569
    FGFR4-IN-20
    		Inhibitor
    FGFR4-IN-20 (comp 11) is an orally active and selective FGFR4 inhibitor with IC50s of 19 and 36 nM against Huh7 cells and FGFR4 enzyme. FGFR4-IN-20 can be used for hepatocellular carcinoma research.
  • HY-158248
    FGFR4-IN-19
    		Inhibitor
    FGFR4-IN-19 (compound 8B) is a potent covalent fibroblast growth factor receptor 4 (FGFR4) inhibitor (IC50=1.2 nM). FGFR4-IN-19 achieves high efficiency and isotype selectivity by covalently targeting a rare cysteine (C552) in the FGFR4 kinase domain. FGFR4-IN-19 can be used for hepatocellular carcinoma (HCC) research.
  • HY-144759
    FGFR4-IN-9
    		Inhibitor
    FGFR4-IN-9 (Compound 6O) is a selective FGFR4 inhibitor with an IC50 of 75.3 nM. FGFR4-IN-9 effectively inhibits both the growth and angiogenesis of HCC.
  • HY-152146
    HDAC-IN-50
    		Inhibitor
    HDAC-IN-50 is a potent and orally active FGFR and HDAC dual inhibitor with IC50 values of 0.18, 1.2, 0.46, 1.4, 1.3, 1.6, 2.6, 13 nM for FGFR1, FGFR2, FGFR3, FGFR4, HDAC1, HDAC2, HDAC6, HDAC8, respectively. HDAC-IN-50 induces Apoptosis and cell cycle arrest at G0/G1 phase. HDAC-IN-50 decreases the expression of pFGFR1, pERK, pSTAT3. HDAC-IN-50 shows anti-tumor activity.
  • HY-168286
    FGFR-IN-16
    		Inhibitor
    FGFR-IN-16 (compound 7N) is a potent inhibitor of FGFR1, FGFR2, and FGFR4, with the IC50s of 8 nM, 4 nM and 3.8 nM, respectively. FGFR-IN-16 plays an important role in cancer research1].
  • HY-147715
    FGFR3-IN-3
    		Inhibitor
    FGFR3-IN-3 (compound 40a) is a potent and pan-FGFR inhibitor, with IC50s of 2.1 nM, 3.1 nM, 4.3 nM and 74 nM for FGFR1, 2, 3, and 4, respectively. FGFR3-IN-3 can be used for the research of bladder cancer.
  • HY-161326
    CXF-007
    		Inhibitor
    CXF-007 is a potent and specific FGFR4 inhibitor with a IC50 value of 7 nM. CXF-007 has antitumor activity.
  • HY-159642G
    TYRA-300 (GMP)
    		Inhibitor
    TYRA-300 GMP is TYRA-300 (HY-159642) produced by using GMP guidelines. TYRA-300 GMP is an orally active, selective inhibitor for FGFR3 with an IC50 of 11 nM. TYRA-300 GMP exhibits antitumor efficacy against urothelial cancers and solid tumors.
  • HY-15599A
    SSR128129E free acid
    		Inhibitor
    SSR128129E free acid is an orally available and allosteric FGFR inhibitor with an IC50 of 1.9 μM for FGFR1.